|Interferon alpha: the salvage therapy for patients with unsatisfactory response to minimal residual disease-directed modified donor lymphocyte infusion|
|Mo Xiaodong; Zhao Xiangyu; Xu Lanping; Liu Daihong; Zhang Xiaohui; Chen Huan; Wang Yu; Huang Xiaojun|
|关键词||interferon alpha hematopoietic stem cell transplantation donor lymphocyte infusion|
|刊名||CHINESE MEDICAL JOURNAL|
|WOS标题词||Science & Technology|
|类目[WOS]||Medicine, General & Internal|
|研究领域[WOS]||General & Internal Medicine|
|关键词[WOS]||STEM-CELL TRANSPLANTATION ; ACUTE MYELOID-LEUKEMIA ; BONE-MARROW-TRANSPLANTATION ; COMPLETE REMISSION ; HIGH-RISK ; IN-VITRO ; RELAPSE ; IMMUNOTHERAPY|
Background Minimal residual disease (MRD)-directedmodified donor lymphocyte infusion (mDLI) is used to treat relapse after hematopoietic stem cell transplantation (HSCT). For patients who experience an unsatisfactory response tomDLI, relapse is usually inevitable. Therefore, we sought to evaluate the efficacy ofinterferon a therapy in these patients.
Methods Regular MRD monitoring was carried out after the HSCT. The patients who were MRD-positive underwent mDLI. Patients with an unsatisfactory response to mDLI received interferon alpha therapy (3 million units, twice weekly) with regular monitoring of MRD. To ensure the immunomodulatory effects of interferon alpha, immunosuppressant treatment would be stopped before interferon alpha treatment.
Results Five patients with an unsatisfactory response to mDLI treatment received interferon alpha (3 had t(8;21) chromosomal translocation acute myeloid leukemia, and 2 had common acute leukemia). They had significantly reduced or resolved MRD. Four patients developed chronic graft-versus-host disease. Two of the 5 patients reported transient fevers, and no significant bone marrow suppression was observed. All of them were in continuous complete remission after interferon alpha treatment. The median survival time was 469 days (range 368-948 days).
Conclusions In patients with an unsatisfactory response to MRD-directed mDLI, interferon alpha may directly or indirectly induce the graft-versus-leukemia effect to improve mDLI efficacy and clear MRD.
|作者单位||Peking Univ, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Inst Hematol, Peoples Hosp, Beijing 100044, Peoples R China|
|Mo Xiaodong,Zhao Xiangyu,Xu Lanping,et al. Interferon alpha: the salvage therapy for patients with unsatisfactory response to minimal residual disease-directed modified donor lymphocyte infusion[J]. CHINESE MEDICAL JOURNAL,2014,127(14):2583-2587.|
|APA||Mo Xiaodong.,Zhao Xiangyu.,Xu Lanping.,Liu Daihong.,Zhang Xiaohui.,...&Huang Xiaojun.(2014).Interferon alpha: the salvage therapy for patients with unsatisfactory response to minimal residual disease-directed modified donor lymphocyte infusion.CHINESE MEDICAL JOURNAL,127(14),2583-2587.|
|MLA||Mo Xiaodong,et al."Interferon alpha: the salvage therapy for patients with unsatisfactory response to minimal residual disease-directed modified donor lymphocyte infusion".CHINESE MEDICAL JOURNAL 127.14(2014):2583-2587.|